Market cap
$7.1M

Exicure Inc. (XCUR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for XCUR, including 3 SEC filings and 1 press release or news item. The most recent was published Nov 12, 2026.

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.

XCUR rankings

Financial highlights

Full financials
Revenue, TTM
$0
Net income, TTM
-$8.28M
Cash
$1.72M

For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks15+100%
2026-05-24: 12026-05-31: 22026-06-07: 12026-06-14: 02026-06-21: 02026-06-28: 22026-07-05: 02026-07-12: 12026-07-19: 02026-07-26: 02026-08-02: 12026-08-09: 12026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 22026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 12026-11-08: 32026-11-15: 0
2026-05-242026-11-15
Mix690d
  • SEC Filings4(67%)
  • Other2(33%)
Activity · 52 weeks3527 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

XCUR FAQ

10 questions
  • What does Exicure Inc. do?
    Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA–based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and...
  • What is the latest news on XCUR?
    In the last 30 days Quantisnow tracked 4 wire items for XCUR: 3 SEC filings and 1 press release or news item. The most recent was published on November 12, 2026.
  • What is XCUR revenue?
    Exicure Inc. (XCUR) reported $0 of revenue for the twelve months ended Jun 30, 2026. Revenue for fiscal 2025 was $0.
  • Is XCUR profitable?
    No. Exicure Inc. reported a net loss of $8.28M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does XCUR have?
    Exicure Inc. reported $1.72M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does XCUR stock trade?
    Exicure Inc. (XCUR) is listed on NASDAQ.
  • What sector and industry is XCUR in?
    Exicure Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about XCUR?
    Across the last 2 analyst actions on Exicure Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Chardan Capital Markets: Neutral with a $0.40 price target on 2021-12-13.
  • What companies are similar to XCUR?
    Notable peers in the same industry include WVE (Wave Life Sciences Inc.), ARWR (Arrowhead Pharmaceuticals Inc.), IONS (Ionis Pharmaceuticals Inc.), ALNY (Alnylam Pharmaceuticals Inc.), SRPT (Sarepta Therapeutics Inc.). Compare XCUR side-by-side with any of them on Quantisnow.
  • How can I track XCUR on Quantisnow?
    Quantisnow aggregates Exicure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow XCUR to receive live email and push alerts on every new disclosure.